Milestone Scientific (MLSS) 10-Q 14 May 21 2021 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 14, 2021
Document Information [Line Items]
Entity Registrant Name	MILESTONE SCIENTIFIC INC.
Entity Central Index Key	0000855683
Trading Symbol	mlss
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		66,755,195
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false
Title of 12(b) Security	Common Stock, par value $.001 per share

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 16,950,710	$ 14,223,917
Accounts receivable, net	978,761	1,080,656
Accounts receivable, related party net	267,300
Prepaid expenses and other current assets	688,820	415,915
Inventories, net	2,020,549	2,420,179
Advances on contracts	753,197	414,202
Total current assets	21,659,337	18,554,869
Furniture, fixtures and equipment, net	27,074	30,729
Intangibles, net	317,896	329,249
Right of use assets	612,576	632,453
Other assets	24,150	24,150
Total assets	22,641,033	19,571,450
Current liabilities:
Accounts payable	694,044	482,972
Accounts payable, related party	184,360	385,138
Accrued expenses and other payables	1,178,907	824,454
Accrued expenses, related party	382,627	586,734
Current portion of finance leases liabilities	7,977	7,796
Current portion of operating lease right-of-use liabilities	73,596	72,031
Deferred profit, related party	241,288	242,589
Note payable	276,180	276,180
Total current liabilities	3,038,979	2,877,894
Finance lease liabilities	26,544	28,607
Operating lease liabilities	538,421	557,981
Total liabilities	3,603,944	3,464,482
Commitments and contingencies
Stockholders’ equity
Common stock, par value $.001; authorized 85,000,000 shares; 66,591,883 shares issued and 66,558,550 shares outstanding as of March 31, 2021; 64,171,435 shares issued and 64,138,102 shares outstanding as of December 31, 2020;	66,591	64,171
Additional paid in capital	121,848,254	117,934,696
Accumulated deficit	(101,858,826)	(100,885,957)
Treasury stock, at cost, 33,333 shares	(911,516)	(911,516)
Total Milestone Scientific Inc. stockholders' equity	19,144,503	16,201,394
Noncontrolling interest	(107,414)	(94,426)
Total stockholders’ equity	19,037,089	16,106,968
Total liabilities and stockholders’ equity	$ 22,641,033	$ 19,571,450

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	85,000,000	85,000,000
Common stock, shares issued (in shares)	66,591,883	64,171,435
Common stock, shares outstanding (in shares)	66,558,550	64,138,102
Treasury stock, at cost, shares (in shares)	33,333	33,333

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Product sales, net	$ 2,924,707	$ 1,811,386
Cost of products sold	1,122,413	527,250
Gross profit	1,802,294	1,284,136
Selling, general and administrative expenses	2,749,299	2,748,043
Research and development expenses	16,444	107,480
Depreciation and amortization expense	20,924	37,219
Total operating expenses	2,786,667	2,892,742
Loss from operations	(984,373)	(1,608,606)
Interest expense, net	(2,535)	(4,097)
Loss before provision for income taxes and net of equity investments	(986,908)	(1,612,703)
Provision for income taxes	(250)	(250)
Loss before equity in net earnings of equity investments	(987,158)	(1,612,953)
Income from China Joint Venture	1,301
Net loss	(985,857)	(1,612,953)
Net loss attributable to noncontrolling interests	(12,988)	(12,738)
Net loss attributable to Milestone Scientific Inc.	$ (972,869)	$ (1,600,215)
Net loss per share applicable to common stockholders—
Basic (in dollars per share)	$ (0.01)	$ (0.03)
Diluted (in dollars per share)	$ (0.01)	$ (0.03)
Weighted average shares outstanding and to be issued—
Basic (in shares)	66,578,435	49,730,252
Diluted (in shares)	66,578,435	49,730,252

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Consultant [Member]Common Stock [Member]	Consultant [Member]Additional Paid-in Capital [Member]	Consultant [Member]Retained Earnings [Member]	Consultant [Member]Noncontrolling Interest [Member]	Consultant [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Treasury Stock [Member]	Total
Balance (in shares) at Dec. 31, 2019						49,410,176
Balance at Dec. 31, 2019						$ 49,410	$ 96,082,324	$ (93,524,297)	$ (67,274)	$ (911,516)	$ 1,628,647
Stock based compensation							30,715				30,715
Common stock issued to employee for compensation expensed in prior periods (in shares)						21,317
Common stock to be issued for payment of consulting services expensed in prior periods (in shares)						1,316
Common stock issued to board of directors for services expensed in prior periods (in shares)		25,000			25,000
Common stock to be issued to employees for bonuses							171,046				171,046
Common stock issued for warrants exercised (in shares)						460,725
Common stock issued for warrants exercised						$ 460	229,902				230,362
Net loss								(1,600,215)	(12,738)		(1,612,953)
Common stock to be issued to employee for compensation						23	14,989				15,012
Common stock issued for warrants						$ 460	229,902				230,362
Balance (in shares) at Mar. 31, 2020						49,893,534
Balance at Mar. 31, 2020						$ 49,893	96,553,976	(95,124,512)	(80,012)	(911,516)	487,829
Balance (in shares) at Dec. 31, 2020						64,171,435
Balance at Dec. 31, 2020						$ 64,171	117,934,696	(100,885,957)	(94,426)	(911,516)	16,106,968
Stock based compensation							113,507				113,507
Common stock issued to employee for compensation expensed in prior periods (in shares)						7,075
Common stock issued to employee for compensation expensed in prior periods						$ 7					7
Common stock to be issued for payment of consulting services expensed in prior periods (in shares)						40,010
Common stock to be issued for payment of consulting services expensed in prior periods						$ 40					40
Common stock issued to board of directors for services expensed in prior periods (in shares)						18,879
Common stock issued to board of directors for services expensed in prior periods						$ 18					18
Number of options exercised (in shares)						435,558
Common stock issued to employee for stock options exercised						$ 436	689,754				690,190
Common stock to be issued to employees for bonuses							100,000				100,000
Common stock issued for warrants exercised (in shares)						1,918,925
Common stock issued for warrants exercised						$ 1,919	3,010,297				3,012,216
Net loss								(972,869)	(12,988)		(985,857)
Common stock issued for warrants						$ 1,919	3,010,297				3,012,216
Balance (in shares) at Mar. 31, 2021						66,591,882
Balance at Mar. 31, 2021						$ 66,591	$ 121,848,254	$ (101,858,826)	$ (107,414)	$ (911,516)	$ 19,037,089

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (985,857)	$ (1,612,953)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	9,572	23,966
Amortization of patents	11,352	13,253
Stock compensation	113,507	30,715
Employees paid in stock	115,000	186,035
Expense paid in stock		25,000
Earnings on China joint venture	(1,301)
Non-cash operating lease expense	1,883	27,627
Changes in operating assets and liabilities:
Decrease in accounts receivable	101,895	421,127
(Increase) in accounts receivable, related party	(267,300)
Decrease in other assets		11,755
(Increase) decrease in inventories	399,630	(102,316)
(Increase) in advances on contracts	(338,995)	(65,171)
(Increase) in prepaid expenses and other current assets	(272,905)	(165,032)
(Decrease) in accounts payable	211,072	64,317
(Decrease) increase accounts payable, related party	(200,778)	30,567
Increase in accrued expenses	339,518	215,437
(Decrease) in accrued expenses, related party	(204,107)	(76,406)
Net cash used in operating activities	(967,814)	(972,079)
Cash flows from investing activities:
Purchase of property and equipment	(5,916)	(7,138)
Net cash used in investing activities	(5,916)	(7,138)
Cash flows from financing activities:
Proceeds from exercise of warrants	3,012,216	230,362
Payments finance lease obligations	(1,883)	(1,442)
Net proceeds from employee options exercised	690,190
Net cash provided by financing activities	3,700,523	228,920
Net increase in cash and cash equivalents	2,726,793	(750,297)
Cash and cash equivalents at beginning of period	14,223,917	1,516,272
Cash and cash equivalents at end of period	16,950,710	765,975
Supplemental non-cash disclosure of cash flow information:
Initial recognition of operating lease-right of use assets		(706,071)
Initial recognition of operating lease right to used liabilities		$ 706,071

Note 1 - Organization and Busin

Note 1 - Organization and Business	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	NOTE 1 All references in this report to “Milestone Scientific,” “us,” “our,” “we,” the “Company” or “Milestone” refer to Milestone Scientific Inc., and its consolidated subsidiaries, Wand Dental, Inc., Milestone Advanced Cosmetic Systems, Inc., Milestone Medical, Inc. and Milestone Education LLC (all described below), unless the context otherwise indicates. Milestone Scientific is the owner of the following registered U.S. trademarks: C ompuDent ; CompuMed ; CompuFlo ; DPS Dynamic Pressure Sensing technology ; Milestone Scientific ; the Milestone logo ; SafetyWand ; STA Single Tooth Anesthesia System ; and The Wand . Milestone Scientific was incorporated in the State of Delaware in August 1989. The Wand CompuDent , STA Single Tooth Anesthesia System CompuMed . CompuDent CompuMed 60 June 2017, 510 CompuFlo March 31, 2021 twelve In December 2016, 510 not 510 510 2019, 510 not 2019 2020. March 31, 2021, not In April June 2020, two $4.6 $13.4 9 March 31, 2021, $16.9 $2.7 December 31, 2020.

Note 2 - Liquidity and Uncertai

Note 2 - Liquidity and Uncertainties	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	NOTE 2 AND UNCERTAINTIES The Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one March 31, 2021, $101,900,000 $973,000 three March 31, 2021. In April June 2020, $4.6 $13.4 9 March 31, 2021, $16.9 $2.7 December 31, 2020. The coronavirus (COVID- 19 December 2019 third 19, three March 31, 2020 19 In addition to our employees, we rely on (i) distributors, agents, and third third third may In addition, it is uncertain as to what effect the continuing spread of COVID- 19

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 3 1. The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), Milestone Advanced Cosmetic (majority owned), Milestone Education (wholly owned) and Milestone Medical (majority owned). All significant, intra-entity transactions and balances have been eliminated in consolidation. 2. The unaudited condensed consolidated financial statements of Milestone Scientific have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information with the instructions for Form 10 8 X. not not may December 31, 2020, 10 3. Certain reclassification has been made to the 2020 2021 no 4. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, cash flow assumptions regarding evaluations for impairment of long-lived assets and going concern considerations, and valuation allowances on deferred tax assets. Actual results could differ from those estimates. 5. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To perform revenue recognition for customer arrangements the Company performs the following five i. identification of the promised goods or services in the contract; ii. determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; iii. measurement of the transaction price, including the constraint on variable consideration; iv. allocation of the transaction price to the performance obligations based on estimated standalone selling prices; and selling prices; and v. recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606, The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products through a global distribution network and that includes both exclusive and non-exclusive distribution agreements with related and third Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon date of shipment. For certain arrangements where the shipping terms are freight-on-board (FOB) destination, revenue is recognized upon delivery. The Company has no Sales Returns The Company records allowances for product returns as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customers' return rights and the Company's historical experience with returns and the amount of product in the distribution channel not may Financing and Payment Our payment terms differ by geography and customer, but payment is generally required within 90 Disaggregation of Revenue We operate in two 11 three March 31, 2021 6. A variable interest entity ("VIE") is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE. Because Milestone Scientific has a variable interest in Milestone China it considered the guidance in ASC 810, ● Power Criterion: The power to direct the activities that most significantly impact the entity's economic performance; and ● Losses/Benefits Criterion: The obligation to absorb losses that could potentially be significant or the right to receive benefits that could potentially be significant to the VIE. Milestone Scientific does not not not 810. 6. 7. Milestone Scientific considers all highly liquid investments purchased with an original maturity of three March 31, 2021, December 31, 2020 $15.0 $13.1 may 8. Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the inability of its customers to make payments on amounts billed. Most credit sales are due within 90 not March 31, 2021 December 31, 2020 $10,000 9. Inventories principally consist of finished goods and component parts stated at the lower of cost ( first first not March 31, 2021, December 31, 2020 , $450,000, $453,000, 4. 10. Investments in which Milestone Scientific can exercise significant influence, but do not may 6. 11. Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from two seven 12. Patents are recorded at cost to prepare and file the applicable documents with the US Patent Office, or internationally with the applicable governmental office in the respective country. The costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. Patents and other developed technology acquired from another business entity will be amortized based on the estimated useful life of the patent. These patents and developed technology are recorded at the acquisition cost. 13. Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not ● significant under performance relative to expected historical or projected future operating results; ● significant changes in the manner of our use of the acquired assets or the strategy for our overall business; ● significant negative industry or economic trends; and ● significant technological changes, which would render the technology obsolete. Recoverability of assets that will continue to be used in the Company's operations is measured by comparing the carrying value to the future net undiscounted cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future revenues, driven by market growth rates, and estimated future costs. 14. On April 27, 2020, $276,000, March 27, 2020. The Loan, which was in the form of a Note dated April 27, 2020, April 27, 2022, 1.00% November 26, 2020. may no may February 15, 2020. may 8. 15. Research and development costs, which consist principally of new product development costs payable to third 16. Milestone Scientific accounts for income taxes pursuant to the asset and liability method which requires deferred income tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. See Note 10. On March 31, 2021 December 31, 2020 no No 2017, 2018, 2019 17. Milestone Scientific presents “basic” earnings (loss) per common share applicable to common stockholders and, if applicable, “diluted” earnings (loss) per common share applicable to common stockholders pursuant to the provisions of ASC 260, Since Milestone Scientific had net losses in the three March 31, 2021 2020 not 6,092,193 1,875,886 March 31, 2021 2020 18. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). We are required to classify fair value measurements in one ● Level 1 ● Level 2 1 ● Level 3 Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and may March 31, 2021 December 31, 2020, not 19. Milestone Scientific accounts for stock-based compensation under ASC 718, 718” 718 20. At the inception of an arrangement, we determine whether an arrangement is, or contains, a lease. An arrangement is, or contains, a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Leases with a term greater than one not 12 not Finance and operating lease right-of-use assets represent the Company's right to use an underlying asset over the lease term, and lease liabilities represent the Company's obligation to make lease payments arising from the lease. These assets and obligations are recognized at the lease commencement date based on the present value of lease payments, net of incentives, over the lease term. The interest rate implicit in our leases is typically not We evaluate the classification of our leases as either finance leases or operating leases. Leases that are economically similar to the purchase of assets are generally classified as finance leases; otherwise, the leases are classified as operating leases. Lease cost for our operating leases is recognized on a straight-line basis over the lease term. Included in lease cost are any variable lease payments incurred in the period that are not 12 14. 22. Recently Adopted Accounting Pronouncements In December 2019, 2019 12, 740 2019 12 December 15, 2020. January 1, 2021, not Recently Issued Accounting Pronouncements In January 2020, 2020 01, 321 323 815 2020 01 December 15, 2021, not August 2020, 2020 06, 470 20 815 40 2020 06 December 15, 2021, not In June 2016, No.2016 13, 326 December 15, 2022.

Note 4 - Inventories

Note 4 - Inventories	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 4 Inventories consist of the following: March 31, 2021 December 31, 2020 Dental finished goods, net $ 1,337,117 $ 1,888,141 Medical finished goods, net 345,754 200,327 Component parts and other materials 337,678 331,711 Total inventories $ 2,020,549 $ 2,420,179 On March 31, 2021 $450,000. December 31, 2020 $450,000 $3,000.

Note 5 - Advances on Contracts

Note 5 - Advances on Contracts	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Advances to Contract Manufacturer [Text Block]	NOTE 5 The advances on contracts represent funding of future STA inventory purchases, epidural instruments, and epidural replacements parts. The balance of the advances as of March 31, 2021 December 31, 2020 $753,000 $414,000,

Note 6 - Investment in and Tran

Note 6 - Investment in and Transactions With Equity Investees	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	NOTE 6 Milestone China Ltd. Ownership In June 2014, $1 40% 75% In first 2020, However, as of the filing date of this Annual Report, due to the COVID- 19 28.4% Milestone Scientific, in previous years, reduced its investment in Milestone China to zero $ 5.9 December 31, 2020, For the three March 31, 2021, $506,400. March 31, 2021 $178,000 not three March 31, 2020. Related Party Transactions Milestone China Distribution Agreement Milestone China is Milestone Scientific's exclusive distributor in China. During 2017 2018, 2018, $2.8 $950,000 United Systems, Inc. Agreement In April 2020, 13 2018, not $370,260 $100,000 April 2020, $170,260 April 23, 2020, $1.59 June 2020, $100,000 July 2020. $1.4 Advanced Cosmetics Systems Agreement In May 2020, 50% $900,000 50% one $900,000 100% Gross Profit Deferral Due to timing differences of when the inventory sold to Milestone China is recognized and when Milestone China sells the acquired inventory to third 323 third At March 31, 2021, December 31, 2020, $241,000 $243,000, three March 31, 2021, 2020 $1,301 third

Note 7 - Patents

Note 7 - Patents	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	NOTE 7 March 31, 2021 Cost Accumulated Amortization Net Patents-foundation intellectual property $ 1,377,863 $ (1,059,966 ) $ 317,897 Total $ 1,377,863 $ (1,059,966 ) $ 317,897 December 31, 2020 Cost Accumulated Amortization Net Patents-foundation intellectual property $ 1,377,863 $ (1,048,614 ) $ 329,249 Total $ 1,377,863 $ (1,048,614 ) $ 329,249 Patents are amortized utilizing the straight-line method over estimated useful lives ranging from 3 20 $11,000 $13,000 three March 31, 2021 March 31, 2020,

Note 8 - Note Payable

Note 8 - Note Payable	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE 8 On April 27, 2020, $276,000, March 27, 2020. 2.5 seven eight April 27, 2022 1.00% November 26, 2020. April 27, 2022 not may no may February 15, 2020. On May 7, 2021, $201,000 $75,000.

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 9— Public Offering and Private Placement In the second 2020, two April 2020, $5.1 5,420,000 2,710,000 $0.95 $1.20 three 3 June 2020, second $14.6 6,770,000 3,749,000 $2.15 $2.60 three 3 Warrants The following table summarizes information about shares issuable under warrants outstanding as of March 31, 2021 Warrant shares outstanding Weighted Average exercise price Weighted Average remaining life Intrinsic value Outstanding at January 1, 2021 6,369,396 $ 1.49 $ 2.48 $ 2,784,117 Issued - Exercised (1,918,925 ) 1.57 - 4,044,164 Expired or cancelled - - - - Outstanding and exercisable at March 31, 2021 4,450,471 $ 2.14 $ 2.26 $ 6,381,930 The following table summarizes information about shares issuable under warrants outstanding as of March 31, 2020 Warrant shares outstanding Weighted Average exercise price Weighted Average remaining life Intrinsic value Outstanding at January 1, 2020 1,074,171 $ 0.50 $ 4.10 $ 956,012 Issued - - - Exercised (460,725 ) 0.50 - 630,389 Expired or cancelled - - - - Outstanding and exercisable at March 31, 2020 613,446 $ 0.50 $ 3.85 $ 460,085 Shares to Be Issued As of March 31, 2021 2020 2,264,127 2,306,698 As of March 31, 2021 2020 144,024 159,835 The following table summarizes information about shares to be issued on March 31, 2021 2020 March 31, 2021 March 31, 2020 Shares-to-be-issued, outstanding January 1, 2021 and 2020, respectively 2,440,878 2,375,760 Granted in current period 33,238 102,768 Issued in current period (65,965 ) (11,995 ) Shares-to be issued outstanding March 31, 2021 and 2020, respectively 2,408,151 2,466,533 Stock Options Plans In June 2011, 2011 "2011 2,000,000 2016 4,000,000. three five March 31, 2021, December 31, 2020, 293,505, 424,425, The Milestone Scientific Inc. 2020 2,000,000 December 2030. may not three five no March 31, 2021 December 31, 2020, Milestone Scientific recognizes compensation expense over the requisite service period and in the case of performance-based options over the period of the expected performance. For the three March 31, 2021 2020, $113,507 $56,988 March 31,2021 $914,389 2.7 A summary of option activity for employees under the plans and changes during the years ended March 31, 2021 2020 Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding January 1, 2021 1,953,443 1.88 3.09 476,964 Granted 32,175 3.11 - - Exercised during 2021 - - - - Forfeited or expired (435,558) 1.58 - - Options outstanding March 31, 2021 1,550,060 1.98 3.62 2,457,153 Exercisable, March 31, 2021 745,045 1.93 2.60 1,222,127 The Company used the following assumptions to calculate the fair value of the stock option grants using the Black-Scholes option pricing model on the measurement date during the three March 31, 2021, 1.42% 89.46% 3 0% $3.11 Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding January 1, 2020 1,212,442 1.71 2.40 - Granted - - - - Exercised during 2020 - - - - Forfeited or expired - - - - Options outstanding March 31, 2020 1,212,442 1.71 2.40 - Exercisable, March 31, 2020 1,117,829 1.84 1.84 - A summary of option activity for non-employees under the plans and changes during the years ended March 31, 2021 2020 Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding January 1, 2021 74,997 1.41 3.18 54,748 Granted 16,666 4.30 Exercised during 2021 - - - - Options outstanding March 31, 2021 91,663 1.87 3.30 161,660 Exercisable, March 31, 2021 52,769 1.34 2.37 117,829 Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding January 1, 2020 49,998 1.87 2.94 - Granted 8,333 1.65 - Exercised during 2020 - - - - Options outstanding March 31, 2020 58,331 1.87 2.94 Exercisable, March 31, 2020 41,663 1.71 2.03 84,579 The fair value of the non-employee options was estimated on the date of grant using the Black Scholes option-pricing model at the date of grant. For the three March 31 ,2021 2021, $10,329 zero The Company used the following assumptions to calculate the fair value of the stock option grants using the Black-Scholes option pricing model on the measurement date during the three March 31, 2021, 0.2% 1.41 86.97% 89.90%, 5 0% $3.57 $4.30 .

Note 10 - Income Taxes

Note 10 - Income Taxes	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 10 The utilization of Milestone Scientific's net operating losses may 382 may 100%

Note 11 - Segment and Geographi

Note 11 - Segment and Geographic Data	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Product Sales and Significant Customers and Vendors Disclosure [Text Block]	NOTE 11 We conduct our business through two not The following tables present information about our reportable and operating segments: Net Sales: Three months ended March 31, 2021 Three months ended March 31, 2020 Dental $ 2,853,657 $ 1,803,586 Medical 71,050 7,800 Total net sales $ 2,924,707 $ 1,811,386 Operating Income (Loss): Three months ended March 31, 2021 Three months ended March 31, 2020 Dental $ 1,126,069 $ 576,386 Medical (895,781 ) (669,814 ) Corporate (1,214,661 ) (1,515,178 ) Total operating loss $ (984,373 ) $ (1,608,606 ) Depreciation and Amortization Three months ended March 31, 2021 Three months ended March 31, 2020 Dental $ 1,706 $ 5,699 Medical 3,851 3,712 Corporate 15,367 27,808 Total depreciation and amortization $ 20,924 $ 37,219 Income (loss) before taxes and equity in earnings of affiliates: Three months ended March 31, 2021 Three months ended March 31, 2020 Dental $ 1,125,154 $ 572,289 Medical (897,051 ) (669,814 ) Corporate (1,215,011 ) (1,515,178 ) Total loss before taxes and equity in earnings of affiliate $ (986,908 ) $ (1,612,703 ) Total Assets: March 31, 2021 December 31, 2020 Dental $ 6,954,380 $ 6,035,645 Medical 1,019,186 923,658 Corporate 14,667,467 12,612,147 Total assets $ 22,641,033 $ 19,571,450 The following table presents information about our operations by geographic area for three March 31, 2021 2020 Three months ended March 31, 2021 Three months ended March 31, 2020 Dental Medical Total Dental Medical Total Domestic: US/Canada Instruments $ 176,016 $ - $ 176,016 $ 525 $ - $ 525 Handpieces 794,984 8,150 803,134 697,360 - 697,360 Accessories 17,908 17,908 22,506 - 22,506 Total Domestic US $ 988,908 $ 8,150 $ 997,058 $ 720,391 $ - $ 720,391 International: Rest of World Instruments $ 383,255 $ 42,500 $ 425,755 $ 242,504 $ 7,600 $ 250,104 Handpieces 954,534 20,400 974,934 830,208 200 830,408 Accessories 20,560 - 20,560 10,483 - 10,483 Total International $ 1,358,349 $ 62,900 $ 1,421,249 $ 1,083,195 $ 7,800 $ 1,090,995 International: China Instruments $ 150,000 $ - $ 150,000 $ - $ - $ - Handpieces 356,400 - 356,400 - - - Other - - - - - - Total International $ 506,400 $ - $ 506,400 $ - $ - $ - Total Product Sales $ 2,856,658 $ 71,050 $ 2,924,707 $ 1,803,586 $ 7,800 $ 1,811,386

Note 12 - Concentrations

Note 12 - Concentrations	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	NOTE 12 Milestone Scientific has informal arrangements with third March 31, 2021, December 31, 2020 . For the three March 31, 2021, 2020 29% 39% one three March 31, 2021 18% 28% 21% March 31, 2021, 69% December 31, 2020.

Note 13 - Related Party Transac

Note 13 - Related Party Transactions	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 13 United Systems Milestone Scientific has a manufacturing agreement with United Systems (whose controlling shareholder, Tom Cheng, is a significant stockholder of Milestone Scientific), the principal manufacturers of its handpieces, pursuant to which it manufactures products under specific purchase orders, but without minimum purchase commitments. Purchases from this manufacturer were approximately $385,000 $544,000 three March 31, 2021 2020 March 31, 2021, December 31, 2020, $179,000 $362,000, March 31, 2021 December 31, 2020, On April 29, 2020, $370,260 6. Milestone China See Note 6. Other As of March 31, 2021, December 31, 2020, zero 275,000, The Company engaged Mr. Trombetta as a consultant for a period of twelve October 1, 2020 September 30, 2021 information and business contacts to the Company and provide consulting services for new International Business and Dental Segment concepts during this twelve $60,000 March 31, 2021, $45,000 In August 2016, $25,000 three March 31, 2021 2020. In January 2017, twelve zero $20,000 three March 31, 2021 2020, September 30, 2020. The Director of Clinical Affairs' royalty fee was approximately $136,000 $95,000 three March 31, 2021 2020, $39,000 three March 31, 2021 2020. March 31, 2021 December 31, 2020, $159,000 $467,000, 14 3

Note 14 - Commitments

Note 14 - Commitments	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 14 ( 1 third January 2021, 2,000 2021. March 31, 2021 $1.5 $504,000 As of March 31, 2021 $102,000 100 $54,000,against January 2021, 100 2021. March 31, 2021 $328,000 $150,000 In February 2021, 246 April 2021. March 31, 2021 $58,000 246 approximately$44,000 ( 2 Operating Leases In June 2015, 774 January 31, 2020 $12,522. not not not In August 2019, not seven 7 January 8, 2020. April 1, 2020 January 1 $9,275 $10,898 $2.00 $11,130 not As of March 31, 2021, $579,990 $612,016, $73,596 $538,421 March 31, 2021, $34,521, $7,977 $26,544 December 31, 2020, $597,770 $630,012, $72,031 $557,981 December 31, 2020, $36,403, $7,796 $28,607 Cash flow information related to the Company's right-of-use assets and related lease liabilities were as follows: Three months ended March 31, Lease cost 2021 2020 Cash paid for operating lease liabilities 31,303 17,264 Cash paid for finance lease liabilities 2,685 2,252 Right-of-use assets obtained in exchange for new operating lease liabilities (1) 663,009 Property and equipment obtained in exchange for new finance lease liabilities 43,242 (1) For the three months ended March 31, 2021, the balance includes operating leases existing as of the adoption of ASC 842 on January 1, 2021. Weighted-average remaining lease term - operating leases (years) 6.0 7.0 Weighted-average remaining lease term- finance leases (years) 3.8 4.8 ( 3 The technology underlying the Safety Wand CompuFlo CompuDent January 1, 2005. 2.5% 5% 2.5% May 9, 2027 – third 13 On October 13, 2020, November 1, 2020, February 28, 2022. On March 2, 2021, May 9, 2027, 2.5% February 25, 2021 5% 2.5% May 9, 2027

Note 15 - Subsequent Events

Note 15 - Subsequent Events	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 15— Exercise of Warrants Since the year ended March 31, 2020, 52,000 $1.20 $62,400. Since the year ended March 31, 2020, 25,000 $2.60 $65,000. On April 6, 2001, five Succession Agreement With respect to (i) the Employment Agreement dated as of July 10, 2017 July 10, 2017 ( $100,000 $200,000, $100,000 $200,000, 9.5 2,000,000 five ten Leonard Osser has announced his intention to resign as Interim Chief Executive Officer of the Company effective May 19, 2021 May 12, 2021 May 19, 2021 $350,000 $400,000 one third two May 19, 2021 December 31, 2021 four Also on May 12, 2021, May 24, 2021. first 500 $200,000 July 2006. August 2005 April 2006,

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	1. The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("GAAP") and include the accounts of Milestone Scientific and its wholly owned and majority owned subsidiaries, including, Wand Dental (wholly owned), Milestone Advanced Cosmetic (majority owned), Milestone Education (wholly owned) and Milestone Medical (majority owned). All significant, intra-entity transactions and balances have been eliminated in consolidation.
Basis of Accounting, Policy [Policy Text Block]	2. The unaudited condensed consolidated financial statements of Milestone Scientific have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information with the instructions for Form 10 8 X. not not may December 31, 2020, 10
Reclassification, Comparability Adjustment [Policy Text Block]	3. Certain reclassification has been made to the 2020 2021 no
Use of Estimates, Policy [Policy Text Block]	4. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions in determining the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to the allowance for doubtful accounts, inventory valuation, cash flow assumptions regarding evaluations for impairment of long-lived assets and going concern considerations, and valuation allowances on deferred tax assets. Actual results could differ from those estimates.
Revenue [Policy Text Block]	5. The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To perform revenue recognition for customer arrangements the Company performs the following five i. identification of the promised goods or services in the contract; ii. determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; iii. measurement of the transaction price, including the constraint on variable consideration; iv. allocation of the transaction price to the performance obligations based on estimated standalone selling prices; and selling prices; and v. recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC 606, The Company derives its revenues from the sale of its products, primarily dental instruments, handpieces, and other related products. The Company sells its products through a global distribution network and that includes both exclusive and non-exclusive distribution agreements with related and third Revenue from product sales is recognized upon transfer of control of a product to a customer, generally upon date of shipment. For certain arrangements where the shipping terms are freight-on-board (FOB) destination, revenue is recognized upon delivery. The Company has no Sales Returns The Company records allowances for product returns as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including the customers' return rights and the Company's historical experience with returns and the amount of product in the distribution channel not may Financing and Payment Our payment terms differ by geography and customer, but payment is generally required within 90 Disaggregation of Revenue We operate in two 11 three March 31, 2021
Consolidation, Variable Interest Entity, Policy [Policy Text Block]	6. A variable interest entity ("VIE") is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity's economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE. Because Milestone Scientific has a variable interest in Milestone China it considered the guidance in ASC 810, ● Power Criterion: The power to direct the activities that most significantly impact the entity's economic performance; and ● Losses/Benefits Criterion: The obligation to absorb losses that could potentially be significant or the right to receive benefits that could potentially be significant to the VIE. Milestone Scientific does not not not 810. 6.
Cash and Cash Equivalents, Policy [Policy Text Block]	7. Milestone Scientific considers all highly liquid investments purchased with an original maturity of three March 31, 2021, December 31, 2020 $15.0 $13.1 may
Accounts Receivable [Policy Text Block]	8. Milestone Scientific sells a significant amount of its product on credit terms to its major distributors. Milestone Scientific estimates losses from the inability of its customers to make payments on amounts billed. Most credit sales are due within 90 not March 31, 2021 December 31, 2020 $10,000
Inventory, Policy [Policy Text Block]	9. Inventories principally consist of finished goods and component parts stated at the lower of cost ( first first not March 31, 2021, December 31, 2020 , $450,000, $453,000, 4.
Equity Method Investments [Policy Text Block]	10. Investments in which Milestone Scientific can exercise significant influence, but do not may 6.
Property, Plant and Equipment, Policy [Policy Text Block]	11. Equipment is recorded at cost, less accumulated depreciation. Depreciation expense is computed using the straight-line method over the estimated useful lives of the assets, which range from two seven
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	12. Patents are recorded at cost to prepare and file the applicable documents with the US Patent Office, or internationally with the applicable governmental office in the respective country. The costs related to these patents are being amortized using the straight-line method over the estimated useful life of the patent. Patents and other developed technology acquired from another business entity will be amortized based on the estimated useful life of the patent. These patents and developed technology are recorded at the acquisition cost.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	13. Long-lived assets with finite lives are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not ● significant under performance relative to expected historical or projected future operating results; ● significant changes in the manner of our use of the acquired assets or the strategy for our overall business; ● significant negative industry or economic trends; and ● significant technological changes, which would render the technology obsolete. Recoverability of assets that will continue to be used in the Company's operations is measured by comparing the carrying value to the future net undiscounted cash flows expected to be generated by the asset or asset group. Future undiscounted cash flows include estimates of future revenues, driven by market growth rates, and estimated future costs.
Debt, Policy [Policy Text Block]	14. On April 27, 2020, $276,000, March 27, 2020. The Loan, which was in the form of a Note dated April 27, 2020, April 27, 2022, 1.00% November 26, 2020. may no may February 15, 2020. may 8.
Research and Development Expense, Policy [Policy Text Block]	15. Research and development costs, which consist principally of new product development costs payable to third
Income Tax, Policy [Policy Text Block]	16. Milestone Scientific accounts for income taxes pursuant to the asset and liability method which requires deferred income tax assets and liabilities to be computed for temporary differences between the financial statement and tax basis of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. See Note 10. On March 31, 2021 December 31, 2020 no No 2017, 2018, 2019
Earnings Per Share, Policy [Policy Text Block]	17. Milestone Scientific presents “basic” earnings (loss) per common share applicable to common stockholders and, if applicable, “diluted” earnings (loss) per common share applicable to common stockholders pursuant to the provisions of ASC 260, Since Milestone Scientific had net losses in the three March 31, 2021 2020 not 6,092,193 1,875,886 March 31, 2021 2020
Fair Value of Financial Instruments, Policy [Policy Text Block]	18. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). We are required to classify fair value measurements in one ● Level 1 ● Level 2 1 ● Level 3 Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of an input to the fair value measurement requires judgment and may March 31, 2021 December 31, 2020, not
Share-based Payment Arrangement [Policy Text Block]	19. Milestone Scientific accounts for stock-based compensation under ASC 718, 718” 718
Lessee, Leases [Policy Text Block]	20. At the inception of an arrangement, we determine whether an arrangement is, or contains, a lease. An arrangement is, or contains, a lease if the arrangement conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Leases with a term greater than one not 12 not Finance and operating lease right-of-use assets represent the Company's right to use an underlying asset over the lease term, and lease liabilities represent the Company's obligation to make lease payments arising from the lease. These assets and obligations are recognized at the lease commencement date based on the present value of lease payments, net of incentives, over the lease term. The interest rate implicit in our leases is typically not We evaluate the classification of our leases as either finance leases or operating leases. Leases that are economically similar to the purchase of assets are generally classified as finance leases; otherwise, the leases are classified as operating leases. Lease cost for our operating leases is recognized on a straight-line basis over the lease term. Included in lease cost are any variable lease payments incurred in the period that are not 12 14.
New Accounting Pronouncements, Policy [Policy Text Block]	22. Recently Adopted Accounting Pronouncements In December 2019, 2019 12, 740 2019 12 December 15, 2020. January 1, 2021, not Recently Issued Accounting Pronouncements In January 2020, 2020 01, 321 323 815 2020 01 December 15, 2021, not August 2020, 2020 06, 470 20 815 40 2020 06 December 15, 2021, not In June 2016, No.2016 13, 326 December 15, 2022.

Note 4 - Inventories (Tables)

Note 4 - Inventories (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, 2021 December 31, 2020 Dental finished goods, net $ 1,337,117 $ 1,888,141 Medical finished goods, net 345,754 200,327 Component parts and other materials 337,678 331,711 Total inventories $ 2,020,549 $ 2,420,179

Note 7 - Patents (Tables)

Note 7 - Patents (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	March 31, 2021 Cost Accumulated Amortization Net Patents-foundation intellectual property $ 1,377,863 $ (1,059,966 ) $ 317,897 Total $ 1,377,863 $ (1,059,966 ) $ 317,897 December 31, 2020 Cost Accumulated Amortization Net Patents-foundation intellectual property $ 1,377,863 $ (1,048,614 ) $ 329,249 Total $ 1,377,863 $ (1,048,614 ) $ 329,249

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrant shares outstanding Weighted Average exercise price Weighted Average remaining life Intrinsic value Outstanding at January 1, 2021 6,369,396 $ 1.49 $ 2.48 $ 2,784,117 Issued - Exercised (1,918,925 ) 1.57 - 4,044,164 Expired or cancelled - - - - Outstanding and exercisable at March 31, 2021 4,450,471 $ 2.14 $ 2.26 $ 6,381,930 Warrant shares outstanding Weighted Average exercise price Weighted Average remaining life Intrinsic value Outstanding at January 1, 2020 1,074,171 $ 0.50 $ 4.10 $ 956,012 Issued - - - Exercised (460,725 ) 0.50 - 630,389 Expired or cancelled - - - - Outstanding and exercisable at March 31, 2020 613,446 $ 0.50 $ 3.85 $ 460,085
Deferred Compensation Arrangement with Individual, Share-based Payments [Table Text Block]	March 31, 2021 March 31, 2020 Shares-to-be-issued, outstanding January 1, 2021 and 2020, respectively 2,440,878 2,375,760 Granted in current period 33,238 102,768 Issued in current period (65,965 ) (11,995 ) Shares-to be issued outstanding March 31, 2021 and 2020, respectively 2,408,151 2,466,533
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding January 1, 2021 1,953,443 1.88 3.09 476,964 Granted 32,175 3.11 - - Exercised during 2021 - - - - Forfeited or expired (435,558) 1.58 - - Options outstanding March 31, 2021 1,550,060 1.98 3.62 2,457,153 Exercisable, March 31, 2021 745,045 1.93 2.60 1,222,127 Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding January 1, 2020 1,212,442 1.71 2.40 - Granted - - - - Exercised during 2020 - - - - Forfeited or expired - - - - Options outstanding March 31, 2020 1,212,442 1.71 2.40 - Exercisable, March 31, 2020 1,117,829 1.84 1.84 - Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding January 1, 2021 74,997 1.41 3.18 54,748 Granted 16,666 4.30 Exercised during 2021 - - - - Options outstanding March 31, 2021 91,663 1.87 3.30 161,660 Exercisable, March 31, 2021 52,769 1.34 2.37 117,829 Number of Options Weighted Averaged Exercise Price $ Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Options Value $ Options outstanding January 1, 2020 49,998 1.87 2.94 - Granted 8,333 1.65 - Exercised during 2020 - - - - Options outstanding March 31, 2020 58,331 1.87 2.94 Exercisable, March 31, 2020 41,663 1.71 2.03 84,579

Note 11 - Segment and Geograp_2

Note 11 - Segment and Geographic Data (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Net Sales: Three months ended March 31, 2021 Three months ended March 31, 2020 Dental $ 2,853,657 $ 1,803,586 Medical 71,050 7,800 Total net sales $ 2,924,707 $ 1,811,386 Operating Income (Loss): Three months ended March 31, 2021 Three months ended March 31, 2020 Dental $ 1,126,069 $ 576,386 Medical (895,781 ) (669,814 ) Corporate (1,214,661 ) (1,515,178 ) Total operating loss $ (984,373 ) $ (1,608,606 ) Depreciation and Amortization Three months ended March 31, 2021 Three months ended March 31, 2020 Dental $ 1,706 $ 5,699 Medical 3,851 3,712 Corporate 15,367 27,808 Total depreciation and amortization $ 20,924 $ 37,219 Income (loss) before taxes and equity in earnings of affiliates: Three months ended March 31, 2021 Three months ended March 31, 2020 Dental $ 1,125,154 $ 572,289 Medical (897,051 ) (669,814 ) Corporate (1,215,011 ) (1,515,178 ) Total loss before taxes and equity in earnings of affiliate $ (986,908 ) $ (1,612,703 ) Total Assets: March 31, 2021 December 31, 2020 Dental $ 6,954,380 $ 6,035,645 Medical 1,019,186 923,658 Corporate 14,667,467 12,612,147 Total assets $ 22,641,033 $ 19,571,450
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Three months ended March 31, 2021 Three months ended March 31, 2020 Dental Medical Total Dental Medical Total Domestic: US/Canada Instruments $ 176,016 $ - $ 176,016 $ 525 $ - $ 525 Handpieces 794,984 8,150 803,134 697,360 - 697,360 Accessories 17,908 17,908 22,506 - 22,506 Total Domestic US $ 988,908 $ 8,150 $ 997,058 $ 720,391 $ - $ 720,391 International: Rest of World Instruments $ 383,255 $ 42,500 $ 425,755 $ 242,504 $ 7,600 $ 250,104 Handpieces 954,534 20,400 974,934 830,208 200 830,408 Accessories 20,560 - 20,560 10,483 - 10,483 Total International $ 1,358,349 $ 62,900 $ 1,421,249 $ 1,083,195 $ 7,800 $ 1,090,995 International: China Instruments $ 150,000 $ - $ 150,000 $ - $ - $ - Handpieces 356,400 - 356,400 - - - Other - - - - - - Total International $ 506,400 $ - $ 506,400 $ - $ - $ - Total Product Sales $ 2,856,658 $ 71,050 $ 2,924,707 $ 1,803,586 $ 7,800 $ 1,811,386

Note 14 - Commitments (Tables)

Note 14 - Commitments (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Lease, Cost and Other Information [Table Text Block]	Three months ended March 31, Lease cost 2021 2020 Cash paid for operating lease liabilities 31,303 17,264 Cash paid for finance lease liabilities 2,685 2,252 Right-of-use assets obtained in exchange for new operating lease liabilities (1) 663,009 Property and equipment obtained in exchange for new finance lease liabilities 43,242 (1) For the three months ended March 31, 2021, the balance includes operating leases existing as of the adoption of ASC 842 on January 1, 2021. Weighted-average remaining lease term - operating leases (years) 6.0 7.0 Weighted-average remaining lease term- finance leases (years) 3.8 4.8

Note 1 - Organization and Bus_2

Note 1 - Organization and Business (Details Textual) $ in Millions	1 Months Ended		3 Months Ended	12 Months Ended
	Jun. 30, 2020USD ($)	Apr. 30, 2020USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Number of Countries in which Entity Operates			60
April 6, 2020 Public Offering [Member]
Proceeds from Issuance of Common Stock		$ 4.6	$ 16.9
June 30, 2020 Public Offering [Member]
Proceeds from Issuance of Common Stock	$ 13.4			$ 2.7

Note 2 - Liquidity and Uncert_2

Note 2 - Liquidity and Uncertainties (Details Textual) - USD ($)	1 Months Ended		3 Months Ended		12 Months Ended
	Jun. 30, 2020	Apr. 30, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Retained Earnings (Accumulated Deficit), Ending Balance			$ (101,858,826)		$ (100,885,957)
Net Income (Loss) Attributable to Parent, Total			(972,869)	$ (1,600,215)
Cash and Cash Equivalents, at Carrying Value, Ending Balance			16,950,710		14,223,917
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total			2,726,793	$ (750,297)
April 6, 2020 Public Offering [Member]
Proceeds from Issuance of Common Stock		$ 4,600,000	$ 16,900,000
June 30, 2020 Public Offering [Member]
Proceeds from Issuance of Common Stock	$ 13,400,000				$ 2,700,000

Note 3 - Summary of Significa_2

Note 3 - Summary of Significant Accounting Policies (Details Textual)	Apr. 27, 2020USD ($)	Mar. 31, 2021USD ($)shares	Mar. 31, 2020shares	Dec. 31, 2020USD ($)
Number of Operating Segments		2
Short-term Investments, Total		$ 15,000,000		$ 13,100,000
Accounts Receivable, Allowance for Credit Loss, Ending Balance		10,000		10,000
Inventory Valuation Reserves, Ending Balance		450,000		453,000
Unrecognized Tax Benefits, Ending Balance		0		$ 0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total		$ 0
Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares		6,092,193	1,875,886
Paycheck Protection Program CARES Act [Member]
Proceeds from Notes Payable, Total	$ 276,000
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)		2 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)		7 years

Note 4 - Inventories (Details T

Note 4 - Inventories (Details Textual) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Inventory Valuation Reserves, Ending Balance	$ 450,000	$ 453,000
Slow Moving Medical Finished Goods [Member]
Inventory Valuation Reserves, Ending Balance	$ 450,000	450,000
Slow Moving Dental Finished Goods [Member]
Inventory Valuation Reserves, Ending Balance		$ 3,000

Note 4 - Inventories - Summary

Note 4 - Inventories - Summary of Inventories (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Component parts and other materials	$ 337,678	$ 331,711
Total inventories	2,020,549	2,420,179
Dental Segment [Member]
Finished goods, net	1,337,117	1,888,141
Medical Segment [Member]
Finished goods, net	$ 345,754	$ 200,327

Note 5 - Advances on Contracts

Note 5 - Advances on Contracts (Details Textual) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Advances on Inventory Purchases	$ 753,197	$ 414,202

Note 6 - Investment in and Tr_2

Note 6 - Investment in and Transactions With Equity Investees (Details Textual) - USD ($)	Apr. 30, 2020	Apr. 29, 2020	Jul. 31, 2020	May 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2018	Dec. 31, 2020	Apr. 23, 2020	Jun. 30, 2014
Revenue from Related Parties					$ 506,400	$ 0
Contract with Customer, Liability, Total					178,000
Income (Loss) from Equity Method Investments, Total					1,301
Acquisition of Advanced Cosmetic Systems [Member]
Business Acquisition, Percentage of Voting Interests Acquired				50.00%
Business Combination, Consideration Transferred, Total				$ 900,000
Business Combination, Percentage of Ownership Interest that Seller of Ownership Interest May Repurchase Within One Year of Sale Date				50.00%
Business Combination, Price at Which the Additional Ownership Interest Acquired May Repurchased Within One Year of Sale Date				$ 900,000
Business Combination, Step Acquisition, Equity Interest in Acquiree, including Subsequent Acquisition, Percentage, Total				100.00%
Manufacturing Agreement for Handpieces [Member]
Related Party Transaction, Purchases from Related Party	$ 370,260	$ 370,260			385,000	$ 544,000
Sale Price in Cash [Member]
Related Party Transaction, Purchases from Related Party	100,000		$ 100,000
Sale Price in Share [Member]
Related Party Transaction, Purchases from Related Party	$ 170,260
Share Price (in dollars per share)									$ 1.59
Milestone China [Member]
Equity Method Investments										$ 1,000,000
Equity Method Investment, Ownership Percentage										40.00%
Financing Receivable, after Allowance for Credit Loss, Total							$ 2,800,000
Proceeds from Collection of Finance Receivables							$ 950,000
Due from Related Parties, Total								$ 1,400,000
Income (Loss) from Equity Method Investments, Total					1,301
Milestone China [Member] | Accounts Receivable from Related Parties [Member]
Equity Method Investment, Deferred Intercompany Profit (Loss)					$ 241,000			243,000
Milestone Beijing [Member] | Milestone China [Member]
Equity Method Investment, Ownership Percentage										75.00%
Anhui [Member]
Equity Method Investments								0
Equity Method Investment, Ownership Percentage					28.40%
Equity Method Investments, Accumulated Loss								$ 5,900,000

Note 7 - Patents (Details Textu

Note 7 - Patents (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Amortization of Intangible Assets, Total	$ 11,352	$ 13,253
Patents [Member]
Amortization of Intangible Assets, Total	$ 11,000	$ 13,000
Patents [Member] | Minimum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	3 years
Patents [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	20 years

Note 7 - Patents - Summary of P

Note 7 - Patents - Summary of Patents (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Patents, cost	$ 1,377,863	$ 1,377,863
Patents, impairment	(1,059,966)	(1,048,614)
Patents, accumulated amortization	317,897	329,249
Foundation Intellectual Property Patents [Member]
Patents, cost	1,377,863	1,377,863
Patents, impairment	(1,059,966)	(1,048,614)
Patents, accumulated amortization	$ 317,897	$ 329,249

Note 8 - Note Payable (Details

Note 8 - Note Payable (Details Textual) - USD ($)	May 07, 2021	Apr. 27, 2020	Mar. 31, 2021	Dec. 31, 2020
Notes Payable, Current, Total			$ 276,180	$ 276,180
Paycheck Protection Program CARES Act [Member]
Proceeds from Notes Payable, Total		$ 276,000
Paycheck Protection Program CARES Act [Member] | Subsequent Event [Member]
Debt Instrument, Decrease, Forgiveness	$ 201,000
Notes Payable, Current, Total	$ 75,000

Note 9 - Stockholders' Equity_2

Note 9 - Stockholders' Equity (Details Textual) - USD ($)	1 Months Ended			3 Months Ended		12 Months Ended
	Jun. 30, 2020	Apr. 30, 2020	Jun. 30, 2011	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 2.14	$ 0.50	$ 1.49	$ 0.50
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance (in shares)				2,408,151	2,466,533	2,440,878	2,375,760
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Amount Capitalized				$ 113,507	$ 56,988
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total				$ 914,389
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)				2 years 255 days
Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Employee [Member]
Share Price (in dollars per share)				$ 3.11
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)				32,175
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				1.42%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate				89.46%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)				3 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate				0.00%
Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Nonemployee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)				16,666	8,333
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)				5 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate				0.00%
Share-based Payment Arrangement, Expense				$ 10,329	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum				0.20%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum				1.41%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum				86.97%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum				89.90%
Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Nonemployee [Member] | Minimum [Member]
Share Price (in dollars per share)				$ 3.57
Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Nonemployee [Member] | Maximum [Member]
Share Price (in dollars per share)				$ 4.30
Stock Option Plan 2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)			2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)			4,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercise Period from Grant Date (Year)			3 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expire Period after Grant Date (Year)			5 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)				293,505		424,425
The 2020 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)				0		0
The 2020 Equity Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)						2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)						3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)						5 years
Chief Executive Officer, Chief Financial Officer and Employees [Member]
Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance (in shares)				2,264,127	2,306,698
Non-Employees [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)				144,024	159,835
Warrants Associated With April 2020 Public Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		2,710,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 1.20
Warrants and Rights Outstanding, Term (Year)		3 years
Warrants Associated With the June 2020 Public Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	3,749,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 2.60
Warrants and Rights Outstanding, Term (Year)	3 years
April 6, 2020 Public Offering [Member]
Proceeds from Issuance of Common Stock, Gross		$ 5,100,000
Stock Issued During Period, Shares, New Issues (in shares)		5,420,000
Share Price (in dollars per share)		$ 0.95
June 30, 2020 Public Offering [Member]
Proceeds from Issuance of Common Stock, Gross	$ 14,600,000
Stock Issued During Period, Shares, New Issues (in shares)	6,770,000
Share Price (in dollars per share)	$ 2.15

Note 9 - Stockholders' Equity -

Note 9 - Stockholders' Equity - Warrants (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Outstanding, number of shares (in shares)	6,369,396	1,074,171	1,074,171
Outstanding, weighted average exercise price (in dollars per share)	$ 1.49	$ 0.50	$ 0.50
Outstanding, weighted average remaining life (Year)	2 years 94 days	3 years 310 days	2 years 175 days	4 years 36 days
Outstanding, intrinsic value	$ 6,381,930	$ 460,085	$ 2,784,117	$ 956,012
Issued, number of shares (in shares)
Issued, weighted average exercise price (in dollars per share)
Issued, weighted average remaining life (Year)
Issued, intrinsic value
Exercised, number of shares (in shares)	(1,918,925)	(460,725)
Exercised, weighted average exercise price (in dollars per share)	$ 1.57	$ 0.50
Expired or cancelled (in shares)
Expired or cancelled, weighted average exercise price (in dollars per share)
Outstanding , number of shares (in shares)	4,450,471	613,446	6,369,396	1,074,171
Outstanding , weighted average exercise price (in dollars per share)	$ 2.14	$ 0.50	$ 1.49	$ 0.50

Note 9 - Stockholders' Equity_3

Note 9 - Stockholders' Equity - Summary of Shares to be Issued (Details) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Shares-to-be-issued, outstanding (in shares)	2,440,878	2,375,760
Granted in current period (in shares)	33,238	102,768
Issued in current period (in shares)	(65,965)	(11,995)
Shares-to be issued outstanding (in shares)	2,408,151	2,466,533

Note 9 - Stockholders' Equity_4

Note 9 - Stockholders' Equity - Summary of Option Activity for Employees and Non-employees (Details) - Share-based Payment Arrangement, Option [Member] - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement, Employee [Member]
Number of options (in shares)	1,953,443	1,212,442	1,212,442
Weighted average exercise price, outstanding (in dollars per share)	$ 1.88	$ 1.71	$ 1.71
Weighted average remaining contractual life, outstanding (Year)	3 years 226 days	2 years 146 days	3 years 32 days	2 years 146 days
Aggregate intrinsic value, outstanding	$ 2,457,153		$ 476,964
Number of options granted (in shares)	32,175
Weighted average exercise price, granted (in dollars per share)	$ 3.11
Weighted average remaining contractual life, granted (Year)
Aggregate intrinsic value, granted
Number of options exercised (in shares)
Weighted average exercise price, exercised (in dollars per share)
Weighted average remaining contractual life, exercised (Year)
Aggregate intrinsic value, exercised
Number of options forfeited and expired (in shares)	(435,558)
Weighted average exercise price, forfeited or expired (in dollars per share)	$ 1.58
Number of options exercisable (in shares)	745,045	1,117,829
Weighted average exercise price, exercisable (in dollars per share)	$ 1.93	$ 1.84
Weighted average remaining contractual life, exercisable (Year)	2 years 219 days	1 year 306 days
Aggregate intrinsic value, exercisable	$ 1,222,127
Number of options (in shares)	1,550,060	1,212,442	1,953,443	1,212,442
Weighted average exercise price, outstanding (in dollars per share)	$ 1.98	$ 1.71	$ 1.88	$ 1.71
Number of options exercised (in shares)
Share-based Payment Arrangement, Nonemployee [Member]
Number of options (in shares)	74,997	49,998	49,998
Weighted average exercise price, outstanding (in dollars per share)	$ 1.41	$ 1.87	$ 1.87
Weighted average remaining contractual life, outstanding (Year)	3 years 109 days	2 years 343 days	3 years 65 days	2 years 343 days
Aggregate intrinsic value, outstanding	$ 161,660		$ 54,748
Number of options granted (in shares)	16,666	8,333
Weighted average exercise price, granted (in dollars per share)	$ 4.30	$ 1.65
Weighted average remaining contractual life, granted (Year)
Aggregate intrinsic value, granted
Number of options exercised (in shares)
Weighted average exercise price, exercised (in dollars per share)
Number of options exercisable (in shares)	52,769	41,663
Weighted average exercise price, exercisable (in dollars per share)	$ 1.34	$ 1.71
Weighted average remaining contractual life, exercisable (Year)	2 years 135 days	2 years 10 days
Aggregate intrinsic value, exercisable	$ 117,829	$ 84,579
Number of options (in shares)	91,663	58,331	74,997	49,998
Weighted average exercise price, outstanding (in dollars per share)	$ 1.87	$ 1.87	$ 1.41	$ 1.87
Number of options exercised (in shares)

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual)	3 Months Ended
	Mar. 31, 2021
Percentage of Valuation Allowance	100.00%

Note 11 - Segment and Geograp_3

Note 11 - Segment and Geographic Data (Details Textual)	3 Months Ended
	Mar. 31, 2021
Number of Reportable Segments	2

Note 11 - Segment and Geograp_4

Note 11 - Segment and Geographic Data - Summary by Reporting and Operating Segments (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Product sales, net	$ 2,924,707	$ 1,811,386
Operating Income (Loss)	(984,373)	(1,608,606)
Depreciation and Amortization	20,924	37,219
Income (loss) before taxes and equity in earnings of affiliates	(986,908)	(1,612,703)
Total assets	22,641,033		$ 19,571,450
Corporate, Non-Segment [Member]
Operating Income (Loss)	(1,214,661)	(1,515,178)
Depreciation and Amortization	15,367	27,808
Income (loss) before taxes and equity in earnings of affiliates	(1,215,011)	(1,515,178)
Total assets	14,667,467		12,612,147
Dental Segment [Member]
Product sales, net	2,856,658	1,803,586
Dental Segment [Member] | Operating Segments [Member]
Product sales, net	2,853,657	1,803,586
Operating Income (Loss)	1,126,069	576,386
Depreciation and Amortization	1,706	5,699
Income (loss) before taxes and equity in earnings of affiliates	1,125,154	572,289
Total assets	6,954,380		6,035,645
Medical Segment [Member]
Product sales, net	71,050	7,800
Medical Segment [Member] | Operating Segments [Member]
Product sales, net	71,050	7,800
Operating Income (Loss)	(895,781)	(669,814)
Depreciation and Amortization	3,851	3,712
Income (loss) before taxes and equity in earnings of affiliates	(897,051)	$ (669,814)
Total assets	$ 1,019,186		$ 923,658

Note 11 - Segment and Geograp_5

Note 11 - Segment and Geographic Data - Summary of Operations by Geographic Area (Details) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Product sales, net	$ 2,924,707	$ 1,811,386
Dental Segment [Member]
Product sales, net	2,856,658	1,803,586
Medical Segment [Member]
Product sales, net	71,050	7,800
Domestic [Member]
Product sales, net	997,058	720,391
Domestic [Member] | Dental Segment [Member]
Product sales, net	988,908	720,391
Domestic [Member] | Medical Segment [Member]
Product sales, net	8,150
Domestic [Member] | Instruments [Member]
Product sales, net	176,016	525
Domestic [Member] | Instruments [Member] | Dental Segment [Member]
Product sales, net	176,016	525
Domestic [Member] | Instruments [Member] | Medical Segment [Member]
Product sales, net
Domestic [Member] | Handpieces [Member]
Product sales, net	803,134	697,360
Domestic [Member] | Handpieces [Member] | Dental Segment [Member]
Product sales, net	794,984	697,360
Domestic [Member] | Handpieces [Member] | Medical Segment [Member]
Product sales, net	8,150
Domestic [Member] | Accessories [Member]
Product sales, net	17,908	22,506
Domestic [Member] | Accessories [Member] | Dental Segment [Member]
Product sales, net	17,908	22,506
Domestic [Member] | Accessories [Member] | Medical Segment [Member]
Product sales, net
Rest of World [Member] | Instruments [Member]
Product sales, net	425,755	250,104
Rest of World [Member] | Instruments [Member] | Dental Segment [Member]
Product sales, net	383,255	242,504
Rest of World [Member] | Instruments [Member] | Medical Segment [Member]
Product sales, net	42,500	7,600
Rest of World [Member] | Handpieces [Member]
Product sales, net	974,934	830,408
Rest of World [Member] | Handpieces [Member] | Dental Segment [Member]
Product sales, net	954,534	830,208
Rest of World [Member] | Handpieces [Member] | Medical Segment [Member]
Product sales, net	20,400	200
Rest of World [Member] | Accessories [Member]
Product sales, net	20,560	10,483
Rest of World [Member] | Accessories [Member] | Dental Segment [Member]
Product sales, net	20,560	10,483
Rest of World [Member] | Accessories [Member] | Medical Segment [Member]
Product sales, net
International [Member]
Product sales, net	1,421,249	1,090,995
International [Member] | Dental Segment [Member]
Product sales, net	1,358,349	1,083,195
International [Member] | Medical Segment [Member]
Product sales, net	62,900	7,800
CHINA
Product sales, net	506,400
CHINA | Dental Segment [Member]
Product sales, net	506,400
CHINA | Medical Segment [Member]
Product sales, net
CHINA | Handpieces [Member]
Product sales, net	356,400
CHINA | Handpieces [Member] | Dental Segment [Member]
Product sales, net	356,400
CHINA | Handpieces [Member] | Medical Segment [Member]
Product sales, net
CHINA | Devices [Member]
Product sales, net	150,000
CHINA | Devices [Member] | Dental Segment [Member]
Product sales, net	150,000
CHINA | Devices [Member] | Medical Segment [Member]
Product sales, net
CHINA | Other Products [Member]
Product sales, net
CHINA | Other Products [Member] | Dental Segment [Member]
Product sales, net
CHINA | Other Products [Member] | Medical Segment [Member]
Product sales, net

Note 12 - Concentrations (Detai

Note 12 - Concentrations (Details Textual) - Customer Concentration Risk [Member]	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Revenue Benchmark [Member] | Domestic Distributor [Member]
Concentration Risk, Percentage	29.00%	39.00%
Number of Customers	1
Revenue Benchmark [Member] | International Distributor [Member]
Concentration Risk, Percentage	28.00%
Accounts Receivable [Member]
Concentration Risk, Percentage			69.00%
Accounts Receivable [Member] | Domestic Distributor [Member]
Concentration Risk, Percentage	18.00%
Accounts Receivable [Member] | International Distributor [Member]
Concentration Risk, Percentage	21.00%

Note 13 - Related Party Trans_2

Note 13 - Related Party Transactions (Details Textual) - USD ($)	Apr. 30, 2020	Apr. 29, 2020	Jan. 31, 2017	Mar. 31, 2021	Mar. 31, 2020	Sep. 30, 2021	Dec. 31, 2020	Feb. 28, 2019
Stock Issued During Period, Value, Issued for Services				$ 18
Director [Member]
Deferred Compensation Arrangement with Individual, Compensation Expense				0
Consultant [Member]
Deferred Compensation Arrangement with Individual, Compensation Expense				45,000
Consultant [Member] | Forecast [Member]
Stock Issued During Period, Value, Issued for Services						$ 60,000
Director of Clinical Affairs [Member]
Royalty Expense				136,000	$ 95,000
Professional Fees				39,000	39,000
Accounts Payable, Related Parties				159,000			$ 467,000
Manufacturing Agreement for Handpieces [Member]
Related Party Transaction, Purchases from Related Party	$ 370,260	$ 370,260		385,000	544,000
Manufacturing Agreement for Handpieces [Member] | Accounts Payable, Related Parties, Current [Member]
Due to Related Parties, Current, Total				179,000			$ 362,000
Consulting Services [Member]
Related Party Transaction, Expenses from Transactions with Related Party				25,000	25,000
Consulting Services [Member] | United Systems [Member]
Shares Issued, Price Per Share (in dollars per share)								$ 275,000
Consultant [Member] | Innovest S.p.A. [Member]
Related Party Transaction, Expenses from Transactions with Related Party				$ 0	$ 20,000
Consulting Services Agreement, Term (Year)			12 years

Note 14 - Commitments (Details

Note 14 - Commitments (Details Textual)	Jan. 01, 2005	Feb. 28, 2021	Jan. 31, 2021	Aug. 31, 2019USD ($)	Jun. 30, 2015USD ($)ft²	Mar. 31, 2021USD ($)	Mar. 02, 2021	Mar. 01, 2021	Dec. 31, 2020USD ($)
Advances on Inventory Purchases						$ 753,197			$ 414,202
Operating Lease, Right-of-Use Asset						579,990			597,770
Operating Lease, Liability, Total						612,016			630,012
Operating Lease, Liability, Current						73,596			72,031
Operating Lease, Liability, Noncurrent						538,421			557,981
Finance Lease, Liability, Total						34,521			36,403
Finance Lease, Liability, Current						7,977			7,796
Finance Lease, Liability, Noncurrent						26,544			$ 28,607
Additional Percentage of Director Compensation on Sales Value Using Certain Specify Technology	2.50%
Additional Percentage of Director Compensation Sales Value Using Other Kind of Technology	5.00%
Interim Chief Executive Officer [Member]
Royalty on Net Sales, Percentage							2.50%
Director Clinical Affair [Member]
Royalty on Net Sales, Percentage							2.50%	5.00%
Office Lease for Headquarter in Livingston, New Jersey [Member]
Area of Rentable Space (Square Foot) | ft²					774
Operating Leases, Monthly Rent Expense					$ 12,522
Lessee, Operating Lease, Term of Contract (Year)				7 years
Lessee, Operating Lease, Electric Charge Per Square Foot				$ 2
Lessee, Operating Lease, Electric Payments, Annually				11,130
Office Lease for Headquarter in Livingston, New Jersey [Member] | Minimum [Member]
Operating Leases, Monthly Rent Expense				9,275
Office Lease for Headquarter in Livingston, New Jersey [Member] | Maximum [Member]
Operating Leases, Monthly Rent Expense				$ 10,898
Purchase Commitment for Devices [Member]
Purchase Commitment Number Of Units			2,000
Purchase Commitment, Remaining Minimum Amount Committed						1,500,000
Advances on Inventory Purchases						$ 504,000
Purchase Commitment for Devices Begining in 2020 [Member]
Purchase Commitment Number Of Units						100
Purchase Commitment, Remaining Minimum Amount Committed						$ 102,000
Advances on Inventory Purchases						54,000
Purchase Commitment For Devices Beginning In 2021 [Member]
Purchase Commitment, Remaining Minimum Amount Committed						328,000
Advances on Inventory Purchases						150,000
Purchase Commitment For Epidural Disposable Kits Beginning In April 2021 [Member]
Purchase Commitment Number Of Units		246
Purchase Commitment, Remaining Minimum Amount Committed						58,000
Advances on Inventory Purchases						$ 44,000

Note 14 - Commitments - Lease E

Note 14 - Commitments - Lease Expense (Details) - USD ($)		3 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Cash paid for operating lease liabilities		$ 31,303	$ 17,264
Cash paid for finance lease liabilities		2,685	2,252
Right-of-use assets obtained in exchange for new operating lease liabilities (1)	[1]		(663,009)
Property and equipment obtained in exchange for new finance lease liabilities			$ (43,242)
Weighted-average remaining lease term - operating leases (years) (Year)		6 years	7 years
Weighted-average remaining lease term- finance leases (years) (Year)		3 years 292 days	4 years 292 days
[1]	For the three months ended March 31, 2021, the balance includes operating leases existing as of the adoption of ASC 842 on January 1, 2021.

Note 15 - Subsequent Events (De

Note 15 - Subsequent Events (Details Textual) - USD ($)	May 24, 2021	May 19, 2021	Jul. 10, 2017	Mar. 31, 2021	Mar. 31, 2020	May 14, 2021	Dec. 31, 2020	Dec. 31, 2019
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 2.14	$ 0.50		$ 1.49	$ 0.50
Proceeds from Warrant Exercises				$ 3,012,216	$ 230,362
Previous President and Chief Executive Officer [Member]
Increase (Decrease) in Deferred Compensation			$ 100,000
Employment Agreement, Base Compensation			200,000
Consultant [Member]
Increase (Decrease) in Deferred Compensation			100,000
Employment Agreement, Base Compensation			$ 200,000
Stock Issued During Period, Shares, Issued for Services (in shares)			2,000,000
Compensation Agreement, Term (Year)			5 years
Chief Financial Officer [Member] | Forecast [Member]
Employment Agreement, Base Compensation	$ 200,000
Subsequent Event [Member] | Chief Executive Officer [Member]
Employment Agreement, Base Compensation		$ 350,000
Employment Agreement, Annual Bonuses		$ 400,000
Warrants with 0.50 Exercise Price [Member] | Subsequent Event [Member]
Stock Issued During Period Shares, Warrants Exercised (in shares)						52,000
Warrants with 1.20 Exercise Price [Member] | Subsequent Event [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)						$ 1.20
Proceeds from Warrant Exercises						$ 62,400
Warrants with 2.60 Exercise Price [Member] | Subsequent Event [Member]
Stock Issued During Period Shares, Warrants Exercised (in shares)						25,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)						$ 2.60
Proceeds from Warrant Exercises						$ 65,000